

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 16, 2023

Bobby Gaspar Chief Executive Officer Orchard Therapeutics plc 245 Hammersmith Road London W6 8PW United Kingdom

> Re: Orchard Therapeutics plc Registration Statement on Form S-3 Filed August 10, 2023 File No. 333-273891

Dear Bobby Gaspar:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Catherine Magazu